Related Experiment Video
Updated: May 16, 2025
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Flecainide for the Treatment of Andersen-Tawil Syndrome
Tomer D Mann1, Ayhan Yoruk1, Raquel A Neves2
1Department of Cardiology, Univrsity of California-San Francisco (UCSF) Medical Center, San Francisco, California, USA.
Background:
Andersen-Tawil syndrome type 1 (ATS1) is a rare arrhythmogenic disorder resulting from loss-of-function mutations in KCNJ2. Although the use of flecainide has been proposed to treat and prevent life-threatening arrhythmic events in ATS1, it has only been tested in small case series with limited follow-up. We performed a multicenter cohort study to determine the impact of flecainide on ATS.
Objectives:
This study aimed to assess the efficacy and safety of flecainide in reducing ventricular arrhythmia and related symptoms in patients with ATS1.
Methods:
Clinical and genetic data from consecutive ATS1 patients from 9 centers were collected and entered into a database at UCSF Medical Center, San Francisco, California, USA, and pooled for analysis.
Results:
The study included 31 ATS1 patients with a median age of 27 years (Q1-Q3: 24-38 years). The median follow-up time was 4.2 years (Q1-Q3: 1.6-9.7 years), and the median daily dose of flecainide was 150 mg (Q1-Q3: 100-200 mg). A positive exercise treadmill test was defined as any ventricular arrhythmia other than occasional single premature ventricular contractions, and was seen in 16 of 18 patients before treatment. This decreased to 5 of 18 patients with flecainide (OR: 0.13; P = 0.035). One episode of nonsustained ventricular tachycardia was observed on exercise treadmill test during flecainide treatment, compared with 6 observed during pretreatment. The ventricular arrhythmia score, defined as the most severe arrhythmia on Holter monitoring, improved in 66% of patients (mean improvement 0.62 ± 1.6 U; P = 0.005). Premature ventricular contraction burden decreased by 84.8% (71.5%-100%), from 22.3% at baseline to 3.8% with flecainide (P < 0.001). While on flecainide, symptomatic patients had a 77.7% chance of becoming symptom-free (95% CI: 56.2%-100%). Most patients (21/25, 84%) reported no side effects. One patient experienced a VT storm while treated with flecainide but tolerated a lower dose with a good response.
Conclusions:
These data demonstrate that flecainide treatment may be effective and well-tolerated in ATS1 patients. The occurrence of an arrhythmic storm in 1 patient underscores the potential for toxicity and mandates careful dose titration monitored by rest and exercise electrocardiogram for QRS widening.
Insights
Flecainide effectively reduces ventricular arrhythmias and symptoms in Andersen-Tawil syndrome type 1 (ATS1) patients. Careful monitoring is essential due to potential toxicity, but most patients tolerate the treatment well.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Andersen-Tawil syndrome type 1 (ATS1) is a rare genetic disorder caused by KCNJ2 mutations, leading to life-threatening arrhythmias.
- Flecainide has been proposed for ATS1 treatment, but evidence from large studies is limited.
Purpose of the Study:
- To assess the efficacy and safety of flecainide in managing ventricular arrhythmias and associated symptoms in ATS1 patients.
- To evaluate flecainide's impact on exercise treadmill test results and Holter monitoring findings.
Main Methods:
- A multicenter cohort study involving 31 ATS1 patients.
- Collection and pooled analysis of clinical and genetic data from nine participating centers.
- Median follow-up of 4.2 years with flecainide treatment.
Main Results:
- Flecainide significantly reduced positive exercise treadmill tests from 18 to 5 patients (OR: 0.13; P=0.035).
- Ventricular arrhythmia scores improved in 66% of patients, and premature ventricular contraction burden decreased by 84.8% (P < 0.001).
- 77.7% of symptomatic patients became symptom-free, with 84% reporting no side effects.
Conclusions:
- Flecainide demonstrates efficacy and good tolerability in ATS1 patients for managing ventricular arrhythmias.
- Potential toxicity necessitates careful dose titration and monitoring via electrocardiogram, especially for QRS widening.
Related Concept Videos
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:28Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:30Electroconvulsive Therapy